Therefore, HER2 emerged as a trustworthy drug target when addressing HER2+ cancers (Baselga and Swain, 2009; Rimawi et al., 2015), ovarian (Menderes et al., 2017; Zanini et al., 2017) and gastric cancers (Ruschoff et al., 2012; Abrahao-Machado and Scapulatempo-Neto, 2016). This evidence concerns the gene ERBB2 and cancer.